In this, the final video in this four-part series, Carl June, MD, reviews the challenges identified with CAR T cell therapy in the hematologic malignancies--including resistance and early relapse in some patients and toxicities (i.e., tumor lysis syndrome, cytokine release syndrome) --as well as the progress made to resolve or ameliorate these concerns and future considerations for the therapy.
To view other parts of this program:
Part 1: Adoptive Cell Therapy - An Introduction
Part 2: CTL019 Therapy in Chronic Lymphocytic Leukemia
Part 3: CTL019 in Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia